Markets:

Overview

News

Currencies

International

Treasuries

Belite Bio, Inc - American Depositary Shares (NQ:BLTE)

153.31 +1.44 (+0.95%)

Delayed Quote Updated: 11:54 AM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Belite Bio, Inc - American Depositary Shares

< Previous 1 2 3 4 Next >

Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease ↗

September 03, 2026

Belite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its new drug application for tinlarebant as a treatment for Stargardt disease type 1, granted the application priority...

Via MarketBeat

Belite Bio Q2 Earnings Call Highlights ↗

August 13, 2026

Belite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its New Drug Application for tinlarebant, an investigational treatment for Stargardt disease, and granted the...

Via MarketBeat

Topics Earnings

Full Transcript: Belite Bio Q2 2026 Earnings Call ↗

August 13, 2026

Belite Bio (NASDAQ:BLTE) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by...

Via Benzinga

Topics Earnings

Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases ↗

July 22, 2026

Panelists at the H.C. Wainwright Sixth Annual Ophthalmology Virtual Conference said investigational therapies for inherited retinal disorders could begin to reshape treatment options for Stargardt...

Via MarketBeat

Belite Bio Inc - ADR (NASDAQ:BLTE) Reports Narrower-Than-Expected Q4 Loss, NDA Submission on Track for 2026 ↗

March 02, 2026

Via Chartmill

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Earnings Outlook For Belite Bio ↗

November 07, 2025

Via Benzinga

Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease ↗

July 09, 2026

Belite Bio (NASDAQ:BLTE) Chief Medical Officer Hendrik Scholl said the company is advancing its lead compound, Tinlarebant, as a potential treatment for Stargardt disease and geographic atrophy...

Via MarketBeat

Belite Bio Q1 Earnings Call Highlights ↗

May 20, 2026

Belite Bio (NASDAQ:BLTE) said it has begun a rolling New Drug Application submission to the U.S. Food and Drug Administration for Tinlarebant in Stargardt disease, while also accelerating preparations...

Via MarketBeat

Topics Earnings

Belite Bio (BLTE) Q1 2026 Earnings Transcript ↗

May 20, 2026

Belite Bio (BLTE) Q1 2026 Earnings Transcript

Via The Motley Fool

Belite Bio's Earnings Outlook ↗

August 08, 2025

Via Benzinga

Earnings Outlook For Belite Bio ↗

May 13, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Insights into Belite Bio's Upcoming Earnings ↗

November 11, 2024

Via Benzinga

Belite Bio (BLTE) Q4 2025 Earnings Call Transcript ↗

March 03, 2026

Belite Bio (BLTE) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Why Belite Bio Stock Soared on Monday ↗

December 01, 2025

The company is now tantalizingly close to commercializing its leading drug candidate.

Via The Motley Fool

Top movers in Monday's pre-market session ↗

December 01, 2025

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Expert Ratings for Belite Bio ↗

December 14, 2023

Via Benzinga

Expert Ratings for Belite Bio ↗

August 10, 2023

Via Benzinga

The Latest Analyst Ratings for Belite Bio ↗

July 25, 2023

Via Benzinga

3 Lesser-Known Healthcare Names With Major Upside in Store ↗

October 02, 2025

These are three healthcare stocks offering a compelling combination of secure business, strong fundamentals, and growth opportunity.

Via MarketBeat

Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday ↗

May 21, 2025

Via Benzinga

Belite Bio Analysts See Potential For Stock Gains With Progress In Key Trials ↗

March 18, 2025

Belite Bio Inc (NASDAQ: BLTE) stock falls after reporting Q3 net loss of $36.1M; analysts maintain Buy/Overweight rating, citing positive trial results.

Via Benzinga

Earnings Scheduled For March 17, 2025 ↗

March 17, 2025

Via Benzinga

Earnings Scheduled For August 11, 2025 ↗

August 11, 2025

Via Benzinga

BLTE Stock Earnings: Belite Bio Misses EPS for Q2 2024 ↗

August 09, 2024

BLTE stock results show that Belite Bio missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

BLTE Stock Earnings: Belite Bio Misses EPS for Q1 2024 ↗

May 14, 2024

BLTE stock results show that Belite Bio missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

August 14, 2023

Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential consideration...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2023 ↗

July 28, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2023 ↗

July 26, 2023

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.